Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1649-1655

  Zhang, Suojun ^a   Xie, Ruifan ^a   Wan, Feng ^a   Ye, Fei ^a   Guo, Dongsheng ^a   Lei, Ting ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Glioma stem cells; Heterogeneity; Phenotype; U251

Indexed keywords

CD133 ANTIGEN; GELATINASE A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; NESTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL CYCLE; CELL HETEROGENEITY; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; GLIOMA STEM CELL; GROWTH CURVE; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84886781729     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1623     Document Type: Article

References (39)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
2. Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer 6: 425-436, 2006.
3. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
4. Yuan X, Curtin J, Xiong Y, et al: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23: 9392-9400, 2004.
5. Galli R, Binda E, Orfanelli U, et al: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021, 2004.
6. Jeon HM, Sohn YW, Oh SY, et al: ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 71: 3410-3421, 2011.
7. Ulasov IV, Nandi S, Dey M, Sonabend AM and Lesniak MS: Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 17: 103-112, 2011.
8. Yamada R and Nakano I: Glioma stem cells: their role in chemoresistance. World Neurosurg 77: 237-240, 2012.
9. Wang J, Wakeman TP, Lathia JD, et al: Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28, 2010.
10. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M and Pytel P: Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38: 243-253, 2011.
11. Bonavia R, Inda MM, Cavenee WK and Furnari FB: Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71: 4055-4060, 2011.
12. Piccirillo SG, Binda E, Fiocco R, Vescovi AL and Shah K: Brain cancer stem cells. J Mol Med (Berl) 87: 1087-1095, 2009.
13. Inda MM, Bonavia R, Mukasa A, et al: Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 1731-1745, 2010.
14. Li Z, Wang H, Eyler CE, Hjelmeland AB and Rich JN: Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 284: 16705-16709, 2009.
15. Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia 59: 1169-1180, 2011.
16. Campos B, Wan F, Farhadi M, et al: Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715-2728, 2010.
17. Pollard SM, Yoshikawa K, Clarke ID, et al: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580, 2009.
18. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
19. Wan F, Zhang S, Xie R, et al: The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 20: 877-889, 2010.
20. Zhang SJ, Ye F, Xie RF, et al: Comparative study on the stem cell phenotypes of C6 cells under different culture conditions. Chin Med J (Engl) 124: 3118-3126, 2011.
21. Laks DR, Masterman-Smith M, Visnyei K, et al: Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 27: 980-987, 2009.
22. Zeppernick F, Ahmadi R, Campos B, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129, 2008.
23. Lottaz C, Beier D, Meyer K, et al: Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70: 2030-2040, 2010.
24. Hua W, Yao Y, Chu Y, et al: The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol 105: 149-157, 2011.
25. McCord AM, Jamal M, Williams ES, Camphausen K and Tofilon PJ: CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 15: 5145-5153, 2009.
26. Chiao MT, Yang YC, Cheng WY, Shen CC and Ko JL: CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo. Curr Neurovasc Res 8: 210-219, 2011.
27. Jamal M, Rath BH, Tsang PS, Camphausen K and Tofilon PJ: The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 14: 150-158, 2012.
28. Wang J, Sakariassen PØ, Tsinkalovsky O, et al: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122: 761-768, 2008.
29. Zheng X, Shen G, Yang X and Liu W: Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 67: 3691-3697, 2007.
30. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
31. Harris MA, Yang H, Low BE, et al: Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 68: 10051-10059, 2008.
32. Bleau AM, Hambardzumyan D, Ozawa T, et al: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.
33. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219, 2005.
34. Stockhausen MT, Kristoffersen K and Poulsen HS: The functional role of Notch signaling in human gliomas. Neuro Oncol 12: 199-211, 2010.
35. Hovinga KE, Shimizu F, Wang R, et al: Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28: 1019-1029, 2010.
36. Xu P, Qiu M, Zhang Z, et al: The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo. J Neurooncol 97: 41-51, 2010.
37. Fan X, Matsui W, Khaki L, et al: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66: 7445-7452, 2006.
38. Heddleston JM, Hitomi M, Venere M, et al: Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des 17: 2386-2401, 2011.
39. Christensen K, Schrøder HD and Kristensen BW: CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol 104: 129-143, 2011.